Skip to content

Flutamide

Flutamide is a medication used in the management of hormone-responsive conditions. Available as a single formulation (Eulexin), it acts by inhibiting the body’s response to androgens. This approach is primarily used in Prostate Cancer.

Eulexin

Prostate Cancer

250mg

Flutamide 250mg tablets, used in the management of prostate cancer. A non-steroidal anti-androgen competing with testosterone at the receptor.

From$2.02/ tabletView

Key points

  • Blocks testosterone from binding to its target cells, cutting off signals that certain cells rely on to grow.
  • Regular liver function tests are required during treatment, particularly for those with existing hepatic impairment.
  • Reported effects include fatigue, hot flashes and gastrointestinal discomfort, with some noting skin sensitivity or reduced libido.

What is Flutamide?

Flutamide belongs to a class of medications known as non-steroidal anti-androgens. It blocks the binding of testosterone to specific cells in the body. By reducing the access of androgens to sensitive tissues, it limits the biological signaling required for certain cellular growth.

Flutamide brands and forms

Flutamide is currently available as a tablet formulation. The specific brand listed here is Eulexin, which is commonly referenced within Oncology Support. Individuals evaluating available medical options often discuss the appropriate formulation with their physician to confirm suitability based on their specific health requirements.

Safety overview for Flutamide

What to check before using this medicine

Regular monitoring of liver function is standard during therapy. Individuals with pre-existing hepatic impairment or those who have had abnormal enzyme levels require careful evaluation.

Possible reactions and tolerability

Common variations in physical response may include feelings of fatigue, hot flashes or gastrointestinal discomfort. Skin sensitivity or changes in libido are also reported by some individuals.

Interactions and health factors

Other medications or supplements might alter the way this compound is processed. Disclosure of all concurrent therapies to a healthcare provider is standard practice. Product labelling and verified clinical sources remain the correct references for specific contraindications, interactions and reactions.

Further reading